Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
作者信息
Ghosh Arun K, Xu Chun-Xiao, Rao Kalapala Venkateswara, Baldridge Abigail, Agniswamy Johnson, Wang Yuan-Fang, Weber Irene T, Aoki Manabu, Miguel Salcedo Gomez Pedro, Amano Masayuki, Mitsuya Hiroaki
机构信息
Department of Chemistry and Medicinal Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN 47907, USA.
出版信息
ChemMedChem. 2010 Nov 8;5(11):1850-4. doi: 10.1002/cmdc.201000318.
Abstract
摘要
相似文献
1
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.利用氧杂三环设计配体探究HIV-1蛋白酶抑制剂中的多药耐药性及蛋白质-配体相互作用。
ChemMedChem. 2010 Nov 8;5(11):1850-4. doi: 10.1002/cmdc.201000318.
2
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.靶向蛋白质主链的HIV蛋白酶抑制剂设计：一种对抗耐药性的有效策略。
Acc Chem Res. 2008 Jan;41(1):78-86. doi: 10.1021/ar7001232. Epub 2007 Aug 28.
3
Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.设计并合成了具有高亲和力 P(2)配体的六氢呋喃并吡喃醇衍生的强效 HIV-1 蛋白酶抑制剂：结构活性研究和生物学评价。
J Med Chem. 2011 Jan 27;54(2):622-34. doi: 10.1021/jm1012787. Epub 2010 Dec 31.
4
Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.新型基于氨苯砜的 P1 取代双芳基衍生物的合成与生物评价作为超高效 HIV-1 蛋白酶抑制剂。
Bioorg Med Chem Lett. 2012 Mar 1;22(5):1976-9. doi: 10.1016/j.bmcl.2012.01.037. Epub 2012 Jan 21.
5
Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.对高度耐药的成熟HIV-1蛋白酶PR20具有更高活性的取代双四氢呋喃蛋白酶抑制剂。
J Med Chem. 2015 Jun 25;58(12):5088-95. doi: 10.1021/acs.jmedchem.5b00474. Epub 2015 Jun 4.
6
Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.以冠状氧三环核心作为P2配体设计和开发高效HIV-1蛋白酶抑制剂以对抗多药耐药HIV变体
J Med Chem. 2017 May 25;60(10):4267-4278. doi: 10.1021/acs.jmedchem.7b00172. Epub 2017 Apr 18.
7
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.基于结构设计新型HIV-1蛋白酶抑制剂以对抗耐药性。
J Med Chem. 2006 Aug 24;49(17):5252-61. doi: 10.1021/jm060561m.
8
Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.基于结构设计具有修饰的P1-联苯配体的强效HIV-1蛋白酶抑制剂：合成、生物学评价及酶-抑制剂X射线结构研究
J Med Chem. 2015 Jul 9;58(13):5334-43. doi: 10.1021/acs.jmedchem.5b00676. Epub 2015 Jun 24.
9
Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors (II).双取代双四氢呋喃部分作为非肽类HIV-1蛋白酶抑制剂中的新型P2配体（II）。
J Med Chem. 2015 May 14;58(9):4029-38. doi: 10.1021/acs.jmedchem.5b00358. Epub 2015 Apr 30.
10
GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.GRL-0519，一种新型含噁三嗪环配体的非肽类 HIV-1 蛋白酶抑制剂（PI），能够在体外强有力地抑制多种对 PI 耐药的 HIV-1 变异体的复制。
Antimicrob Agents Chemother. 2013 May;57(5):2036-46. doi: 10.1128/AAC.02189-12. Epub 2013 Feb 12.
引用本文的文献
1
Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance.超越达芦那韦：新一代 HIV-1 蛋白酶抑制剂抵抗耐药性的最新进展。
Chem Commun (Camb). 2022 Oct 20;58(84):11762-11782. doi: 10.1039/d2cc04541a.
2
HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics.带有 10 种洛匹那韦和达芦那韦耐药突变的 HIV-1 蛋白酶表现出改变的抑制、结构重排和极端动力学。
J Mol Graph Model. 2022 Dec;117:108315. doi: 10.1016/j.jmgm.2022.108315. Epub 2022 Sep 1.
3
Phosphine-catalyzed divergent domino processes between γ-substituted allenoates and carbonyl-activated alkenes.磷化氢催化的γ-取代的联烯酸酯与羰基活化烯烃之间的发散性多米诺反应。
Chem Sci. 2022 Feb 11;13(11):3161-3168. doi: 10.1039/d1sc06364b. eCollection 2022 Mar 16.
4
The Pseudo-Symmetric -benzyl Hydroxyethylamine Core in a New Series of Heteroarylcarboxyamide HIV-1 Pr Inhibitors: Synthesis, Molecular Modeling and Biological Evaluation.新型杂芳基羧酰胺 HIV-1 蛋白酶抑制剂中伪对称 -苄基羟乙基胺核心：合成、分子模拟与生物评价。
Biomolecules. 2021 Oct 26;11(11):1584. doi: 10.3390/biom11111584.
5
Nature Inspired Molecular Design: Stereoselective Synthesis of Bicyclic and Polycyclic Ethers for Potent HIV-1 Protease Inhibitors.受自然启发的分子设计：用于高效HIV-1蛋白酶抑制剂的双环和多环醚的立体选择性合成
Asian J Org Chem. 2018 Aug;7(8):1448-1466. doi: 10.1002/ajoc.201800255. Epub 2018 Jun 8.
6
Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I.带有 HIV-1 蛋白酶耐药突变 V32I、I47V 和 V82I 的抗病毒抑制剂的结构研究。
Biochem Biophys Res Commun. 2019 Jun 30;514(3):974-978. doi: 10.1016/j.bbrc.2019.05.064. Epub 2019 May 12.
7
Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.设计、合成及 X 射线研究强效 HIV-1 蛋白酶抑制剂，其中包含作为 P2 配体的氨基噻吩并[2,3-d]嘧啶和氨基四氢萘甲酰胺衍生物。
Eur J Med Chem. 2018 Dec 5;160:171-182. doi: 10.1016/j.ejmech.2018.09.046. Epub 2018 Sep 18.
8
Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap-Core Interface of HIV-1 Protease.耐药性突变L76V改变了HIV-1蛋白酶的瓣-核心界面处的非极性相互作用。
ACS Omega. 2018 Sep 30;3(9):12132-12140. doi: 10.1021/acsomega.8b01683. Epub 2018 Sep 27.
9
HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment.人类免疫缺陷病毒相关神经认知障碍（HAND）与用于抗逆转录病毒治疗的脑渗透性蛋白酶抑制剂的前景
Med Res Arch. 2017 Apr;5(4). Epub 2017 Apr 15.
10
Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.含三环稠合环系作为新型 P2 配体的高效抗 HIV-1 蛋白酶抑制剂的设计与合成：构效关系研究、生物学及 X 射线结构分析。
J Med Chem. 2018 May 24;61(10):4561-4577. doi: 10.1021/acs.jmedchem.8b00298. Epub 2018 May 15.
本文引用的文献
1
TOTAL SYNTHESIS OF GINKGOLIDE A.银杏内酯A的全合成
Tetrahedron Lett. 1988;29(26):3205-3206. doi: 10.1016/0040-4039(88)85122-0. Epub 2001 Dec 10.
2
SYNTHESIS AND OPTICAL RESOLUTION OF HIGH AFFINITY P-LIGANDS FOR HIV-1 PROTEASE INHIBITORS.HIV-1蛋白酶抑制剂高亲和力P-配体的合成与光学拆分
Tetrahedron Lett. 1995 Jan 23;36(4):505-508. doi: 10.1016/0040-4039(94)02296-N. Epub 2000 Jun 14.
3
Highly conserved glycine 86 and arginine 87 residues contribute differently to the structure and activity of the mature HIV-1 protease.高度保守的甘氨酸 86 和精氨酸 87 残基对成熟 HIV-1 蛋白酶的结构和活性有不同的贡献。
Proteins. 2010 Mar;78(4):1015-25. doi: 10.1002/prot.22625.
4
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.以吡咯烷酮和恶唑烷酮作为新型P1'-配体设计HIV-1蛋白酶抑制剂以增强与蛋白酶的主链结合相互作用：合成、生物学评价及蛋白质-配体X射线研究
J Med Chem. 2009 Jul 9;52(13):3902-14. doi: 10.1021/jm900303m.
5
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.柔性环状醚/聚醚作为新型HIV-1蛋白酶抑制剂的P2配体：设计、合成、生物学评价及蛋白质-配体X射线研究
J Med Chem. 2008 Oct 9;51(19):6021-33. doi: 10.1021/jm8004543. Epub 2008 Sep 11.
6
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.靶向蛋白质主链的HIV蛋白酶抑制剂设计：一种对抗耐药性的有效策略。
Acc Chem Res. 2008 Jan;41(1):78-86. doi: 10.1021/ar7001232. Epub 2007 Aug 28.
7
Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.新型蛋白酶二聚化非肽基小分子抑制剂对HIV-1复制的强效抑制作用
J Biol Chem. 2007 Sep 28;282(39):28709-28720. doi: 10.1074/jbc.M703938200. Epub 2007 Jul 17.
8
Why do patients fail HIV therapy?为什么患者的抗逆转录病毒治疗会失败？
Int J Clin Pract. 2007 Jun;61(6):983-90. doi: 10.1111/j.1742-1241.2007.01383.x.
9
Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.HIV-1蛋白酶及突变体V82A和I84V与沙奎那韦的原子分辨率晶体结构。
Proteins. 2007 Apr 1;67(1):232-42. doi: 10.1002/prot.21304.
10
Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance.双四氢呋喃：地瑞那韦的优势配体及新一代抗耐药性的HIV蛋白酶抑制剂。
ChemMedChem. 2006 Sep;1(9):939-50. doi: 10.1002/cmdc.200600103.
Zotero 插件